جست‌وجوی استاد و پژوهشگر

Kathrin Schumannمشاهده پروفایل

استادیار

• CRISPR-based Gene Editing
• Immune Cell Engineering
• Cell Therapy Development
• +۳ مورد دیگر

Prof. Dr. Kathrin Schumann is an Assistant Professor at the Technical University of Munich (TUM), leading the 'Engineering Immune Cells for Therapy' group within the TUM School of Medicine and Health. Her research focuses on CRISPR-based engineering of human immune cells to develop novel therapies for autoimmune and tumor diseases. She holds a doctorate from the Max Planck Institute of Biochemistry and has conducted postdoctoral research at the University of California, San Francisco, under Professors Alex Marson and Jeffrey Bluestone. Dr. Schumann’s academic career includes a Presidential Postdoc Fellowship at Novartis (Basel) and a tenure-track appointment at TUM since 2018. Her work emphasizes genomic editing of T cells to study gene function and improve cell therapy safety. Key research themes include CRISPR-mediated gene silencing, T cell receptor engineering, and HIV-host interaction studies. Education: Bachelor/Master in Biochemistry, University of Tübingen PhD, Max Planck Institute of Biochemistry (Martinsried) Postdoc, University of California, San Francisco (UCSF) Her research has yielded breakthroughs in CRISPR applications for T cell therapy, including PD-1 disruption to enhance anti-tumor efficacy and targeted editing of T cell receptors. Awards include a DFG research grant (2016). Notable achievements include the development of CRISPR ribonucleoprotein platforms for primary T cells and insights into metabolic checkpoints in T cell exhaustion. Her lab collaborates globally to translate CRISPR-based discoveries into clinical therapies.

Franz Lennard Ricklefsمشاهده پروفایل

استاد

• Neurosurgery
• Neuro-oncology
• Molecular Neurobiology
• +۵ مورد دیگر

Prof. Dr. med. Franz Lennard Ricklefs is a Senior Physician and Head of the Working Group at the Department of Neurosurgery, University of Hamburg Faculty of Medicine. He is a Medical Specialist in Neurosurgery with cross-disciplinary expertise in neuro-oncology, molecular pathology, and extracellular vesicle research. Affiliations: University Medical Center Hamburg-Eppendorf (UKE), European Liquid Biopsy Society (ELBS), International Consortium on Meningiomas (ICOM) Research Interests: His work focuses on neurosurgical oncology, particularly glioblastoma and meningioma pathobiology. He investigates DNA methylation patterns, extracellular vesicle biomarkers, and liquid biopsy implementation in clinical neuro-oncology. Additional interests include surgical outcomes for epilepsy and aneurysm management. Article Trends: Over the last decade, Dr. Ricklefs has published extensively on: Extracellular vesicle applications as liquid biopsy markers DNA methylation subclasses for glioblastoma and meningioma Multicenter surgical outcome benchmarking Immune evasion mechanisms in neuro-oncology Technological innovations in neurosurgical visualization Molecular characterization of rare CNS tumors Professional Contributions: He co-authored the MISEV2023 guidelines for extracellular vesicle studies and participates in international consensus reviews for meningioma classification. His collaborations span institutions across Europe and North America.

Guojun Chenمشاهده پروفایل

استادیار

• Biomaterials
• Nanomedicine
• Tissue Engineering
• +۵ مورد دیگر

Guojun Chen is an Assistant Professor at the Department of Biomedical Engineering and a member of the Rosalind & Morris Goodman Cancer Institute (GCI) at McGill University . His research focuses on engineering intelligent biomaterials for precision medicine , with emphasis on non-viral genome editing , cold atmospheric plasma (CAP) therapy , and biomaterials-mediated immunotherapy . The lab operates in a multidisciplinary environment , integrating principles from materials science , chemistry , biology , and health sciences . Education : Ph.D. from University of Wisconsin-Madison (2017), Postdoc at UCLA (2020) Research Themes : Genome Editing Delivery : Designing non-viral vectors for efficient CRISPR/Cas9 delivery in vivo. CAP-mediated Immunotherapy : Developing portable cold plasma devices to synergize with immune checkpoint blockade and study CAP’s immunological mechanisms. Biomaterials-based Immunotherapy : Reprogramming tumor microenvironments using bioresponsive materials to enhance immune responses. Publication Trends : Recent work spans responsive nanomaterials , genomic editing systems , and plasma oncology , with a focus on cancer immunotherapy , diabetes diagnostics , and bioinspired medical devices . Scientific Awards : Canada Research Chair (2024, 2025) McGill's President's Prize for Emerging Researchers (2025) FRQS Chercheurs-boursiers (2022) Chinese Association for Biomaterials Young Investigator Award (2022) NSERC Discovery Grant (2021) Advising & Grants : Supervises 14 current graduate and undergraduate students. Secured $5M+ in funding from CIHR , NSERC , CCS , and CFI , including multi-institutional collaborations with Dr. Morag Park , Dr. Réjean Lapointe , and Dr. Ian Watson .

Kjetil Taskénمشاهده پروفایل

استاد

• Immunoregulation
• Cancer Immunology
• Precision Medicine
• +۲ مورد دیگر

Kjetil Taskén is a full Professor at the Institute for Clinical Medicine, Faculty of Medicine, University of Oslo , and serves as the Director of the Institute for Cancer Research, Oslo University Hospital . He leads the OUS Center for Precision Medicine in Cancer (SEPREK) since 2021 and has held multiple leadership roles in molecular medicine initiatives, including Director of the Norwegian Centre for Molecular Medicine (NCMM) and co-founder of Bioteknologisenteret. Current affiliations: University of Oslo | Oslo University Hospital Education: Dr.med. (Molecular Cell Biology) | Cand.med. | Research Leadership Course Research interests include immunoregulation in cancer , precision oncology , cellular signal transduction in disease , and drug development targeting immune checkpoints . His work bridges translational immunology and molecular oncology , with a focus on regulatory T cell modulation for cancer therapy. Scientific contributions span high-impact publications on regulatory T cell inhibition , precision medicine implementation , and signal pathway drug targeting . Recent articles highlight collaborations across Europe (PCM4EU, PRIME-ROSE) and Norway (IMPRESS-Norway), with methodological advances in tumor microenvironment modeling and mutation timing analysis . Awards : King Olav V Cancer Research Prize | Anders Jahre Medical Prize | Faculty Medal (UiO) | Norwegian Academy of Science and Letters Leadership : Director of NCMM | Founder of Bioteknologisenteret | Head of multiple national cancer research initiatives Labs and teams include the Cancer Immunology Section at Oslo University Hospital and affiliations with the K. G. Jebsen Center for B-Cell Malignancies , where he co-leads research groups.

Andrew Bassettمشاهده پروفایل

پژوهشگر

• Genome Engineering
• Neurodegenerative Diseases
• Stem Cell Research
• +۵ مورد دیگر

Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.

• Virology
• Molecular Pathology
• Host-Pathogen Interactions
• +۵ مورد دیگر

Dr. Richard Y. Zhao is a tenured Professor in the Department of Pathology and Microbiology-Immunology at the University of Maryland School of Medicine. His research combines molecular biology, fission yeast genetics, mammalian biology, and virology to study virus-host interactions, particularly for HIV and Zika virus. He previously held academic positions at Northwestern University and Columbia University and has contributed to over 120 peer-reviewed articles. B.S., China Oceanography University (1981) M.S., Oregon State University (1995) Ph.D., Oregon State University (1991) Postdoctoral Training, Columbia University (1991-1992) Dr. Zhao's research focuses on: Virus-host interactions and pathogenicity High-throughput drug screening for antivirals Role of viral proteins in neuroinflammation and cancer Translational genomics in precision medicine His recent publications highlight SARS-CoV-2 ORF3a, Zika envelope proteins, and HIV protease inhibitors, emphasizing host-pathogen mechanisms across species. He has served on NIH panels and editorial boards for journals like Cell Research and Retrovirology . Scientific awards include: Fellow, American Academy of Microbiology (2019) Bernard L Mirkin Endowed Chair (2001-2004) Honorary Director, Shandong Gallo Institute (2009) Distinguished Service from SCBA (2015) Outstanding Service from CBA-USA (2016) Dr. Zhao also contributes to clinical diagnostics and personalized medicine through molecular testing and pharmacogenetics programs.

Sebastian Hillerمشاهده پروفایل

استاد

• Structural Biology
• NMR Spectroscopy
• Protein Folding
• +۴ مورد دیگر

Professor Sebastian Hiller is a Full Professor at the Biozentrum of the University of Basel, Switzerland, where he leads a research group focused on structural biology and biophysics. His laboratory specializes in using nuclear magnetic resonance (NMR) spectroscopy to elucidate the structures and functions of proteins and their interactions at the atomic level. His research spans several key areas including molecular chaperones and protein folding mechanisms, outer membrane protein biogenesis in bacteria, and kinase signaling pathways. Notably, his group has made significant contributions to understanding how chaperones like trigger factor function, the mechanisms of outer membrane protein assembly through the Bam complex, and dynamic kinase interactions. Their work has direct implications for neurodegenerative diseases and antibiotic development. The Hiller lab's recent publications demonstrate a strong focus on NMR methodology development, protein folding dynamics, and structural mechanisms of antibiotic action. Their research on darobactin's mechanism of action against Gram-negative bacteria represents a significant advance in antibiotic discovery. The group frequently publishes in high-impact journals including Nature, Science, and Nature Communications. ICMRBS Founder's Medal (2018) EMBO Young Investigator (2014) ERC starting grant (2011) SNSF professorship (2010) SNSF scholarship for young researchers (2008) Professor Hiller supervises numerous PhD students and postdoctoral researchers, with many alumni having secured prestigious positions in academia and industry. His laboratory maintains strong collaborations across multiple institutions and has received significant funding through ERC grants and other competitive mechanisms. The Hiller group also operates advanced NMR facilities that serve the broader research community at the University of Basel.

• Immunology
• Virology
• Infectious Diseases
• +۶ مورد دیگر

Paul Klenerman is a Professor at the Nuffield Department of Medicine within the Medical Sciences Division , University of Oxford. His research focuses on immune responses to infectious diseases including HIV, hepatitis B/C, and SARS-CoV-2, with emphasis on T-cell biology, vaccine development, and host-pathogen dynamics. Email: paul.klenerman@medawar.ox.ac.uk Collaborators: Ellie Barnes (Oxford), Adrian Hill (Oxford), Georg Lauer (Harvard), Robert Thimme (Freiburg), and others across 12 institutions. Key research themes include: CD161++/MAIT cell biology (bacterial/viral defense, liver immunology), HCV immune defense (vaccine trials using adenoviral vectors), and memory inflation (persistent immune responses post-viral infections). Recent publications (2024-2025) span vaccine immunology (hybrid immunity, bivalent boosters), liver immunobiology (MAIT cell repair mechanisms), infectious disease dynamics (HCV persistence, dengue progression), and single-cell analysis of gut/lung pathologies.

Xinxin Songمشاهده پروفایل

استادیار

• Cell Death Mechanisms
• Ferroptosis
• Apoptosis
• +۴ مورد دیگر

Xinxin Song, M.D., Ph.D., is an Assistant Professor in the Department of Surgery at the University of Texas Southwestern Medical Center. She holds a medical degree from Peking University Health Science Center and a Ph.D. from Peking Union Medical College. After post-doctoral training at the University of Pittsburgh, she became a Research Assistant Professor at Northwestern University's Feinberg School of Medicine before joining UT Southwestern in 2020. Her lab focuses on understanding mechanisms of cell death (apoptosis, ferroptosis, pH-dependent death, immunogenic cell death) and their interplay with drug resistance, tumor microenvironment, and cancer immunogenicity. Education: M.D., Health Science Center, Peking University Ph.D., Peking Union Medical College Post-doctoral Training, University of Pittsburgh School of Medicine Research Interests: Mechanisms of programmed cell death (apoptosis, ferroptosis) Drug resistance in cancer Tumor microenvironment dynamics Immunogenic cell death pathways Labs/Teams: Established her independent lab in the Department of Surgery at UT Southwestern in 2023

• Systems Biology
• Cancer Research
• Drug Resistance
• +۷ مورد دیگر

Sampsa Hautaniemi is a Professor at the Department of Biochemistry and Developmental Biology within the Faculty of Medicine at the University of Helsinki. He serves as Principal Investigator of the Systems Biology of Drug Resistance in Cancer research group and holds docentship in the Faculty of Medicine. Professor Hautaniemi actively supervises doctoral students across multiple programs including the Doctoral Programme in Biomedicine, Doctoral Programme in Clinical Research, and Doctoral Programme in Integrative Life Science. His research focuses on systems biology approaches to understand drug resistance mechanisms in cancer, particularly ovarian cancer. His work integrates computational biology, genomics, epigenetics, and bioinformatics to develop precision medicine approaches for cancer treatment. His laboratory develops innovative computational methods and experimental models including patient-derived organoids to study tumor evolution, identify therapeutic targets, and predict treatment responses. Analysis of his recent publications reveals a strong emphasis on understanding tumor heterogeneity, clonal evolution during therapy, and the development of computational tools for cancer genomics. His work spans multiple disciplines including cancer biology, computational biology, immunology, and precision medicine, with a particular focus on high-grade serous ovarian cancer as a model system. Scientific Awards: The Anders Jahre Medical Prize to young medical scientists (2014) for outstanding research on systems biology and cancer The Finnish Medical Foundation 50-years jubileum award (2010) Professor Hautaniemi has supervised numerous doctoral students and early-career researchers, contributing significantly to cancer research education. His research is supported by multiple active projects including the DECIDER project (Clinical Decision via Integrating Multiple Data Levels to Overcome Chemotherapy Resistance in High-Grade Serous Ovarian Cancer) funded until 2026, as well as projects from the Academy of Finland, Cancer Foundation, and industry partners like Orion Corporation. His laboratory maintains a patient-derived organoid biobank for high-grade serous ovarian cancer and develops computational tools like Jellyfish for visualizing tumor evolution.

Xin Luمشاهده پروفایل

دانشیار

• Cancer Biology
• Tumor Microenvironment
• Tumor Immunology and Immunotherapy
• +۱۲ مورد دیگر

Xin Lu is the John M. and Mary Jo Boler Collegiate Associate Professor in the Department of Biological Sciences at the University of Notre Dame. She is a full member of the Harper Cancer Research Institute (HCRI), the Boler-Parseghian Center for Rare and Neglected Diseases (CRND), and the Tumor Microenvironment and Metastasis Program at the Indiana University Simon Comprehensive Cancer Center. Her research spans tumor immunology, immunotherapy, metastasis, and multi-omics, with a focus on prostate, breast, and rare cancers. Ph.D. in Molecular Biology, Princeton University (2004–2010) B.S. in Biological Sciences, Tsinghua University, China (2000–2004) Postdoctoral Fellow, Dana-Farber Cancer Institute and M.D. Anderson Cancer Center (2010–2016) Assistant to Associate Professor, University of Notre Dame (2017–Present) Dr. Lu's research investigates the molecular and cellular mechanisms of tumor-immune crosstalk, particularly the role of myeloid-derived suppressor cells (MDSCs) and neutrophils in promoting immunotherapy resistance. Her lab uses genetically engineered mouse models, functional genomics, single-cell and spatial transcriptomics, and high-throughput screening to uncover novel therapeutic targets. A major focus is on how cancer-cell-intrinsic oncogenic signaling shapes the immunosuppressive tumor microenvironment. Her recent publications reveal mechanisms such as Acod1-mediated ferroptosis resistance in neutrophils, Pygo2-driven immunosuppression in prostate cancer, and the efficacy of ketogenic diets in overcoming checkpoint blockade resistance. These studies span multiple disciplines including cancer biology, immunology, metabolism, epigenetics, and bioengineering, reflecting a highly integrative approach to immuno-oncology. Jane Coffin Childs Postdoctoral Fellow John M. and Mary Jo Boler Faculty Appointment Cluster Chair, Cellular & Molecular Biology, IBMS PhD Program Junior Chair, Boler-Parseghian Center for Rare and Neglected Diseases Dr. Lu mentors a diverse team of graduate students, postdoctoral fellows, and undergraduates. Her lab is actively recruiting and has secured funding from federal agencies and private foundations. She collaborates with chemists, bioengineers, and bioinformaticians to develop novel therapeutics, including antibody-drug conjugates, CAR-NK cells, and small-molecule inhibitors. Her lab also develops innovative platforms like mini-tumor chips for immunotherapy evaluation. Her lab maintains affiliations with multiple interdisciplinary centers including the Warren Family Center for Drug Discovery, Eck Institute for Global Health, and Berthiaume Institute for Precision Health, underscoring her collaborative and translational research vision.

Feyruz V. Rassoolمشاهده پروفایل

استاد

• DNA damage and repair
• Genomic instability
• Epigenetic therapy
• +۷ مورد دیگر

Feyruz V. Rassool is a Professor at the University of Maryland School of Medicine, with primary appointment in Radiation Oncology. She serves as Co-director of the Experimental Therapeutics Program at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) and holds an adjunct Associate Professor position at VARI’s Center for Epigenetics. Her research focuses on DNA damage/repair pathways in cancer, particularly their therapeutic exploitation through PARP and DNMT inhibitors. Education: B.Sc. in Human Genetics (1983, University College London), Ph.D. in Biological Sciences (1990, Royal Postgraduate Medical School) Postdoctoral Training: University of Chicago (1990-1994) Her work explores the intersection of DNA repair , epigenetics , and mitochondrial dysfunction to develop novel therapies for breast, ovarian, lung, and leukemias. Key projects include STING-dependent interferon signaling , pathogen mimicry in cancer cells, and metastasis suppression through PARPi/epigenetic combinations. Dr. Rassool is part of the SU2C Epigenetics Dream Team and has secured multiple grants from NCI, NIH, and the Adelson Medical Research Foundation. Her recent preclinical studies with PARP/DNMT inhibitors are being translated into Phase I/II trials for AML and TNBC. Scientific Awards Ziskin Award (2012) NCI-SPORE Grant Co-Leader NIH/NCI P30 CA134274 Support Grant She has mentored 13 PhD/postgraduate researchers and collaborates on clinical trials with Pfizer, VARI-SU2C, and ASTRO. Her lab employs techniques like DNA repair assays , RNAseq , and mouse xenograft models to investigate mechanisms of action for epigenetic drugs.

• Neuro-oncology
• Neuropathology
• Glioblastoma
• +۳ مورد دیگر

Professor Patrick Harter is a faculty member at the Institute of Neuropathology, Ludwig Maximilian University of Munich (LMU), where he leads research in neuro-oncology and molecular diagnostics of CNS tumors. His work focuses on glioblastoma, meningioma, and brain metastasis, with emphasis on epigenetic mechanisms like DNA methylation and metabolic adaptations in the tumor microenvironment. Research interests span: Molecular classification of brain tumors using DNA methylation profiling Therapeutic targeting of BRAF/MEK and PI3K/Akt/mTOR pathways Role of hypoxia and metabolic plasticity in treatment resistance Liquid biopsy development for non-invasive tumor monitoring His recent publications demonstrate a strong trend toward integrating epigenetic, metabolic, and immunotherapeutic approaches. Articles frequently explore: Novel biomarkers for tumor grading and prognosis Mechanisms of therapy resistance in gliomas Impact of tumor microenvironment on metastasis

Rex Hungمشاهده پروفایل

دانشیار

• Bone and Soft Tissue Pathology
• Cardiovascular Pathology
• Pulmonary Pathology
• +۳ مورد دیگر

Rex Hung is an Associate Professor of Pathology at Harvard Medical School and serves as an Associate Pathologist at Massachusetts General Hospital . His academic career focuses on Bone and Soft Tissue Pathology , Cardiovascular Pathology , and Pulmonary Pathology , with significant contributions to cancer research.

Zhi-Ping Fengمشاهده پروفایل

پژوهشگر

• Bioinformatics
• Genomics
• Proteomics
• +۳ مورد دیگر

Dr. Zhi-Ping Feng is a Bioinformatician at the John Curtin School of Medical Research (JCSMR), Australian National University (ANU). Her research focuses on integrating omics data with protein structure-function relationships to study interactions between macromolecules. She has expertise in analyzing genomic and transcriptomic data (e.g., RNA-Seq, ChIP-Seq) and protein structure determination via nuclear magnetic resonance (NMR) spectroscopy. Previously, she held a Senior Research Fellow position at the Walter and Eliza Hall Institute (WEHI) from 2009, working on quality control in omics research and genomic data analysis. Her postdoctoral work at WEHI (2002–2005) involved structural biology of malaria-related proteins, supported by an Australian Postdoctoral Fellowship. She holds a PhD in protein bioinformatics from China and a physics background from Peking University. Education: PhD in Protein Bioinformatics (China) Bachelor’s in Physics, Peking University Research Interests: Her work bridges computational biology and structural biology, with emphasis on: Intrinsically unstructured proteins (IUPs) and their applications in malaria proteomics Omics data integration for disease modeling (e.g., cancer, diabetes, neurodegeneration) Protein-protein interaction networks and structural bioinformatics Publications: Recent work spans cancer immunotherapy, miRNA regulation in retinal degeneration, and T cell biology, with contributions to understanding Wnt signaling in joint replacement complications and genetic fusions in pediatric brain tumors. Awards: Australian Postdoctoral Fellowship (2005) Grants/Teams: Currently affiliated with ANU Bioinformatics Consultancy, supporting translational medical research in immunology, cancer, and genomics. Labs/Teams: Collaborates with the JCSMR’s multidisciplinary teams focusing on biomedical informatics and translational research.